加载中
NASDAQHealthcareBiotechnology
最新数据
US$6.635
−US$0.095 · -1.41%
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
常规交易时段
US$6.635
−US$0.095 · -1.41%
盘中时间采用ET。市场数据可能有所延迟。
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
日内区间
当前US$6.635
52周区间
当前US$6.635
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
60
合理估值
情绪
49
多空交织
风险
66
高风险
动量
19
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
日内区间
当前US$6.635
52周区间
当前US$6.635
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
